Eli Lilly Says Phase 3 Trial of Tirzepatide Met Primary, Secondary Endpoints
Eli Lilly and Co (LLY.US) has a potential first-in-class oral small molecule that significantly reduces Lp(a) levels in adults at high risk of cardiovascular events.
Ruth Gimeno, Vice President of eli lilly and co Diabetes and Metabolism Research Group, said: "We are pleased to see these promising results and look forward to further exploring the next steps of muvalaplin's development."
Evercore Maintains Eli Lilly and Co(LLY.US) With Hold Rating
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,010
Weight-loss version of semaglutide launched in the Chinese market! novo-nordisk a/s (NVO.US) unlocks new growth engine.
novo-nordisk a/s launched Wegovy in china, with prices lower than in the usa; this is an important step for the company to intensify its investment in the rapidly growing market in china.
Top Gap Ups and Downs on Monday: TSLA, SMCI, LYFT and More
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}